Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34NSCLC 9Meningeal Carcinomatosis 5Adenocarcinoma of Lung 5Lung Neoplasms 4Brain Neoplasms 4Respiratory Tract Neoplasms 1Pleural Effusion, Malignant 1Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1Multiple Primary Lung Cancers 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1Adenocarcinoma 1

Interventions

Cisplatin 8Carboplatin 8Bevacizumab 8Pleurodesis 7Talc 6Paclitaxel 6Docetaxel 5Povidone-Iodine 4Doxycycline 4Taxes 3Gemcitabine 3Drug Therapy 3Chest Tubes 3aldesleukin 2Zoledronic Acid 2Trastuzumab 2Thoracoscopy 2Sodium Chloride 2Silver Nitrate 2Pharmaceutical Preparations 2Nivolumab 2Interleukin-2 2Fluorodeoxyglucose F18 2Fentanyl 2Erlotinib Hydrochloride 2Cetuximab 2Bortezomib 2viscum album peptide 1tocilizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pleural Effusion, Malignant × aflutinib × Clear all
NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Jiangmen Central Hospital

Phase 2 Not yet recruiting
63 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡